Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Prelude Therapeutics Incorporated - Common Stock (NQ:PRLD)

2.120 +0.010 (+0.47%)
Streaming Delayed Price Updated: 2:57 PM EST, Feb 18, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 94,743
Open 2.110
Bid (Size) 2.100 (200)
Ask (Size) 2.120 (200)
Prev. Close 2.110
Today's Range 2.090 - 2.190
52wk Range 0.6101 - 4.220
Shares Outstanding 54,808,715
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
The $71 Billion Cancer Shift: Why The FDA Is Speeding Up
Issued on behalf of Oncolytics Biotech Inc. 
From Equity Insider
Via GlobeNewswire
News headline image
Why Did PRLD Stock Surge 13% Today? ↗
Prelude Therapeutics said on Tuesday that the FDA gave clearances to proceed with early-stage trials for its experimental drug PRT12396. 
Via Stocktwits

Performance

YTD
-22.3%
-22.3%
1 Month
+15.2%
+15.2%
3 Month
+26.2%
+26.2%
6 Month
+137.3%
+137.3%
1 Year
+123.4%
+123.4%

More News

Read More
News headline image
Prelude Therapeutics Receives FDA Clearance of Investigational New Drug Application (IND) for PRT12396, a Mutant-selective JAK2V617F Inhibitor
From Prelude Therapeutics, Incorporated
Via GlobeNewswire
News headline image
Cancer Drug Developers Secure Regulatory Clarity as FDA Reshapes Approval Standards
From Equity Insider
Via GlobeNewswire
News headline image
Prelude Therapeutics Presents Data at the 2025 ASH Annual Meeting from its Myeloproliferative Neoplasm (MPN) Programs
From Prelude Therapeutics, Incorporated
Via GlobeNewswire
News headline image
PRLD Investors Have Opportunity to Join Prelude Therapeutics Incorporated Fraud Investigation with the Schall Law Firm
From Schall Law
Via GlobeNewswire
News headline image
PRLD Investors Have Opportunity to Join Prelude Therapeutics Incorporated Fraud Investigation with the Schall Law Firm
From Schall Law
Via GlobeNewswire
News headline image
Targeted Cancer Therapies Gain Momentum as Precision Market Surges Past $106B
Via FinancialNewsMedia
News headline image
Targeted Cancer Therapies Gain Momentum as Precision Market Surges Past $106B
From FN Media Group LLC
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
Via Benzinga
News headline image
Prelude Therapeutics Inc. (NASDAQ:PRLD) Beats Q3 2025 Earnings Estimates and Extends Cash Runway ↗
Via Chartmill
News headline image
Prelude Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
From Prelude Therapeutics, Incorporated
Via GlobeNewswire
News headline image
PRLD Investors Have Opportunity to Join Prelude Therapeutics Incorporated Fraud Investigation With the Schall Law Firm
From The Schall Law Firm
Via Business Wire
News headline image
In today's session, these stocks are experiencing unusual volume. ↗
Via Chartmill
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
Via Benzinga
News headline image
Which stocks are experiencing notable movement on Tuesday? ↗
Via Chartmill
News headline image
On Tuesday, there are stocks with unusual volume. Let's take a look. ↗
Via Chartmill
News headline image
Tuesday's session: top gainers and losers ↗
Via Chartmill
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
Via Benzinga
News headline image
These stocks are gapping in today's session ↗
Via Chartmill
News headline image
Dow Dips Over 400 Points; Pfizer Earnings Top Estimates ↗
Via Benzinga
Topics Stocks
News headline image
Tuesday's pre-market session: top gainers and losers ↗
Via Chartmill
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
Via Benzinga
News headline image
Prelude Therapeutics Announces Strategic Business Update
From Prelude Therapeutics, Incorporated
Via GlobeNewswire
News headline image
Prelude Therapeutics Announces Exclusive Option Agreement with Incyte to Advance Mutant Selective JAK2V617F JH2 Inhibitors
From Prelude Therapeutics, Incorporated
Via GlobeNewswire

Frequently Asked Questions

Is Prelude Therapeutics Incorporated - Common Stock publicly traded?
Yes, Prelude Therapeutics Incorporated - Common Stock is publicly traded.
What exchange does Prelude Therapeutics Incorporated - Common Stock trade on?
Prelude Therapeutics Incorporated - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Prelude Therapeutics Incorporated - Common Stock?
The ticker symbol for Prelude Therapeutics Incorporated - Common Stock is PRLD on the Nasdaq Stock Market
What is the current price of Prelude Therapeutics Incorporated - Common Stock?
The current price of Prelude Therapeutics Incorporated - Common Stock is 2.120
When was Prelude Therapeutics Incorporated - Common Stock last traded?
The last trade of Prelude Therapeutics Incorporated - Common Stock was at 02/18/26 02:57 PM ET
What is the market capitalization of Prelude Therapeutics Incorporated - Common Stock?
The market capitalization of Prelude Therapeutics Incorporated - Common Stock is 116.19M
How many shares of Prelude Therapeutics Incorporated - Common Stock are outstanding?
Prelude Therapeutics Incorporated - Common Stock has 116M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.